Spyre Therapeutics (SYRE) recently accelerated its Phase 2 SKYWAY basket trial by completing enrollment for the rheumatoid arthritis sub study of SPY072 ahead of schedule, with topline data now guided for Q3 2026.
See our latest analysis for Spyre Therapeutics.
The accelerated SKYWAY timeline comes on top of a sharp run, with Spyre Therapeutics posting a 30 day share price return of 18.51% and a 90 day share price return of 58.81%. The 1 year total shareholder return of 272.01% and 3 year total shareholder return of more than 6x highlight how momentum has built over a longer window despite some earlier periods of weaker performance.
If you are looking for more ideas in this corner of the market, it could be worth seeing which other healthcare names are catching attention through 36 healthcare AI stocks.
With shares now at US$47.58 and a market value of about US$3.7b after a strong run, the key question is whether Spyre Therapeutics is still priced below its potential or if markets are already incorporating expectations of the next phase of growth.
Preferred Price to Book: Is It Justified?
On a P/B of 6.7x at a last close of $47.58, Spyre Therapeutics trades at a clear premium to the wider US Biotechs industry average of 2.2x, even though it is still loss making and generates less than $1m in revenue.
The P/B multiple compares the market value of the equity to the company’s book value. In this case it is one of the few usable yardsticks because Spyre Therapeutics has no meaningful revenue and is forecast to remain unprofitable over the next 3 years. For pre revenue, clinical stage biotechs, a richer P/B often reflects investor focus on the asset base, pipeline potential and available funding rather than current profitability.
Here, the stock screens as good value versus a peer group with an average P/B of 10.1x, yet it also screens as expensive versus the broader US Biotechs industry at 2.2x. That mix suggests investors are paying up compared to the sector overall while still seeing the name as relatively appealing against a narrower set of higher multiple peers. The market is implicitly weighing the early stage pipeline, continuing losses and the fact that earnings are forecast to decline on average by 18.5% per year over the next 3 years.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price to book ratio of 6.7x (ABOUT RIGHT)
However, you still need to weigh the ongoing losses of $126.542m and the risk that key clinical trials or regulatory outcomes may not match current expectations.
Find out about the key risks to this Spyre Therapeutics narrative.
Next Steps
If this seems optimistic, now is a good time to look under the hood yourself, review the key concerns, and form your own stance by checking the 4 important warning signs.
Ready for more investment ideas?
If you stop at one stock, you could miss other opportunities that fit your goals, so take a few minutes to scan fresh ideas tailored to different priorities.
- Target potential mispricing by reviewing companies that look attractively valued on key fundamentals through the 58 high quality undervalued stocks.
- Strengthen your income focus by zeroing in on established payers using the 13 dividend fortresses.
- Prioritize resilience by filtering for companies with robust finances through the solid balance sheet and fundamentals stocks screener (40 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com